Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Although PARP1 was found at BRG1 positive/H3K27ac negative promoters of highly expressed genes in a transformed breast cancer cell line, its transcriptional activity was limited to genes simultaneously controlled by BRG1 and EP300, indicating that the ADP-ribosylation of EP300 plays a dominant role in the regulation of BRG1-EP300-driven transcription.
|
31614656 |
2019 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Brahma related gene 1 (BRG1) regulates breast cancer cell migration and invasion by activating MUC1 transcription.
|
30824191 |
2019 |
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
However, subgroup analysis based on tumor type showed that the correlation between BRG1 expression and poor prognosis was only prevalent in CRC and breast cancer.
|
29288038 |
2018 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
This work has established BRG1 as an attractive target for breast cancer therapy.
|
28421159 |
2017 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, we applied RWCFusion to breast cancer and found that top 13 gene fusions, such as BCAS3-BCAS4, NOTCH-NUP214, MED13-BCAS3 and CARM-SMARCA4, have been previously proved to be drivers for breast cancer.
|
27506935 |
2016 |
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
BRG1 is a well-characterized tumor suppressor in some human cancers, but is frequently overexpressed without mutation in other cancers, including breast cancer.
|
27223259 |
2016 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the role of BRG1 in breast cancer development and progression is not fully understood.
|
27630343 |
2016 |
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Since ABC transporters and their induction by chemotherapy drugs are a major cause of chemoresistance and treatment failure, these results support the idea that targeting the enzymatic activity of BRG1 would be an effective adjuvant therapy for breast cancer.
|
27029062 |
2016 |
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that both BRG1 and BRM are overexpressed in most primary breast cancers independent of the tumor's receptor status.
|
25808524 |
2015 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results highlight the importance of BRG1 in breast cancer pathogenesis and BRG1 may serve as a prognostic marker as well as a potentially selective therapeutic target.
|
23533649 |
2013 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
MGD |
We also demonstrate that Brg1+/- mammary tumors have relatively heterogeneous gene expression profiles with similarities and differences compared to other mouse models of breast cancer.
|
17637742 |
2008 |
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings suggest that the prohibitin/Brg1/Brm node is a major cellular target for estrogen antagonists, and thereby also implicate prohibitin/Brg1/Brm as potentially important targets for breast cancer therapy.
|
15141164 |
2004 |